179 related articles for article (PubMed ID: 15291805)
1. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.
Valent P; Ghannadan M; Akin C; Krauth MT; Selzer E; Mayerhofer M; Sperr WR; Arock M; Samorapoompichit P; Horny HP; Metcalfe DD
Eur J Clin Invest; 2004 Aug; 34 Suppl 2():41-52. PubMed ID: 15291805
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis.
Metcalfe DD
Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
[TBL] [Abstract][Full Text] [Related]
5. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
6. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis.
Ruano I; Gargini R; Izquierdo M
Br J Haematol; 2010 Jan; 148(1):59-68. PubMed ID: 19804454
[TBL] [Abstract][Full Text] [Related]
7. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
8. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
9. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
11. Biology, classification and treatment of human mastocytosis.
Valent P
Wien Klin Wochenschr; 1996; 108(13):385-97. PubMed ID: 8766423
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
13. Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis.
Sundram UN; Natkunam Y
J Cutan Pathol; 2007 Apr; 34(4):289-95. PubMed ID: 17381798
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.
Arock M; Valent P
Expert Rev Hematol; 2010 Aug; 3(4):497-516. PubMed ID: 21083038
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, progression patterns and prognostication in mastocytosis.
Sperr WR; Valent P
Expert Rev Hematol; 2012 Jun; 5(3):261-74. PubMed ID: 22780207
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
Valent P; Sperr WR; Schwartz LB; Horny HP
J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
[TBL] [Abstract][Full Text] [Related]
18. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
[TBL] [Abstract][Full Text] [Related]
19. The biology of Kit in disease and the application of pharmacogenetics.
Akin C; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
[TBL] [Abstract][Full Text] [Related]
20. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.
Molderings GJ; Kolck UW; Scheurlen C; Brüss M; Homann J; Von Kügelgen I
Scand J Gastroenterol; 2007 Sep; 42(9):1045-53. PubMed ID: 17710669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
